SCHEMBL28697197

SCHEMBL28697197

CC1(C)OB(c2cnc(COC(N)=O)nc2)OC1(C)C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DGAT1 O75907 2/20 0.43
▸ F11 P03951 3/20 0.38
▸ GSK3A P49840 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ PDGFRB P09619 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ FFAR1 O14842 1/20 0.37
▸ F2 P00734 2/20 0.36
▸ PRSS1 P07477 2/20 0.36
▸ PRSS2 P07478 2/20 0.36
▸ PRSS3 P35030 2/20 0.36
▸ CA1 P00915 3/20 0.36
▸ CA2 P00918 3/20 0.36
▸ CA9 Q16790 3/20 0.36
▸ LMNA P02545 1/20 0.35
▸ AAK1 Q2M2I8 1/20 0.35
▸ LPL P06858 1/20 0.33
▸ LIPG Q9Y5X9 1/20 0.33
▸ HIF1A Q16665 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12457977 0.85 DGAT1 (0.49) DGAT1F11GSK3AGSK3BROCK2
SCHEMBL21293596 0.78 DGAT1 (0.40) DGAT1GSK3AGSK3BFFAR1LPL
SCHEMBL5336869 0.78 F11 (0.56) F11F2PRSS1PRSS2PRSS3
SCHEMBL23287138 0.77 SMN1; SMN2 (0.43) DGAT1GSK3AGSK3BPDGFRBKDR
SCHEMBL28507924 0.77 F11 (0.37) DGAT1F11GSK3AGSK3BROCK2
SCHEMBL4206551 0.77 DGAT1 (0.49) DGAT1GSK3AGSK3BROCK2PDGFRB
SCHEMBL28499822 0.76 DGAT1 (0.58) DGAT1F11ROCK2PDGFRBKDR
SCHEMBL20338099 0.76 FFAR1 (0.43) DGAT1F11GSK3AGSK3BPDGFRB
SCHEMBL25369384 0.75 LPL (0.41) DGAT1F11GSK3AGSK3BFFAR1
SCHEMBL1284703 0.74 LPL (0.44) DGAT1F11GSK3AGSK3BFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114044800-A Aryl, heteroaryl and heterocyclic compounds for the treatment of medical disorders 艾其林医药公司 2022-02-15 — — CN disclosed
Send feedback